Pembrolizumab-Induced Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma: A Case Report-Reference-Cited by-同舟云学术

Pembrolizumab-Induced Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma: A Case Report

Published:2020-04 Issue:4 Volume:42 Page:292-296
ISSN:0193-1091
Container-title:The American Journal of Dermatopathology
language:en
Short-container-title:

Author:

Robinson Shamika,Saleh Jasmine,Curry Jonathan,Mudaliar Kumaran

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Dermatology,General Medicine,Pathology and Forensic Medicine

Reference15 articles.

1. Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis;Abe;J Dermatol.,2015

2. Stevens-johnson syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention;Miliszewski;Am J Med.,2016

3. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy;Goldinger;Clin Cancer Res.,2016

4. Epidermal programmed cell death-ligand1 expression in TEN associated with nivolumab therapy;Vivar;J Cutan Pathol.,2017

5. Toxic epidermal necrolysis‐like reaction with severe cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma;Nayar;J Immunother.,2016

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review;Frontiers in Immunology;2024-07-12

2. Paraneoplastic dermatomyositis and Stevens-Johnson syndrome related to immunotherapy;Immunotherapy;2024-06-18

3. Immune checkpoint inhibitor associated epidermal necrosis, beyond SJS and TEN: a review of 98 cases;Archives of Dermatological Research;2024-05-25

4. Pembrolizumab-induced Stevens-Johnson syndrome/Toxic Epidermal Necrolysis in a Vietnamese patient with nonsmall-cell lung cancer;Asia Pacific Allergy;2023-12-18

5. SJS/TEN immune-related dermatologic reaction secondary to immune checkpoint inhibitor pembrolizumab in skin of color;Gynecologic Oncology Reports;2023-12